Bellicum Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bellicum Pharmaceuticals generated cash of -$25,783,000, which is less than the previous year. Cash used in financing activities reached the amount of $0 last year. Net change in cash is therefore -$25,820,000.
Cash Flow
| 2013 | -7.61M | -366.33K | 17.51M |
|---|---|---|---|
| 2014 | -57.30M | -804.12K | 238.54M |
| 2015 | -35.72M | -86.45M | 818K |
| 2016 | -50.44M | 2.05M | 20.92M |
| 2017 | -72.98M | -3.25M | 78.48M |
| 2018 | -74.78M | 10.41M | 68.10M |
| 2019 | -77.56M | 48.85M | 74.08M |
| 2020 | -56.65M | 14.08M | -14.23M |
| 2021 | -23.10M | 893K | 32.87M |
| 2022 | -25.78M | -21K | 0 |
BLCM Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 47.65M | 36.99M | 93.81M | 48.66M | 45.02M | 42.78M | 70.24M | 191.60M | 11.16M | 1.63M |
Operating activities | ||||||||||
Net income | -24.97M | -9.70M | -7.72M | -112.47M | -98.03M | -91.77M | -69.24M | -48.54M | -83.96M | -7.96M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 11K | 138K | 1.87M | 8.50M | 6.69M | 3.56M | 2.30M | 1.19M | 666.60K | 587.24K |
Stock-based compensation expense | 2.60M | 3.43M | 5.03M | 7.33M | 13.82M | 13.56M | 12.33M | 8.40M | 911.64K | 390.59K |
| Deferred income tax benefit | 2.60M | 3.43M | 5.03M | 7.33M | 13.82M | 13.56M | 12.33M | 8.40M | 911.64K | 390.59K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 205 | 0 | 301K | 606K | -589K | 14K | 106K | -142K | 447.63K | -745.54K |
Inventories | 0 | 0 | -301K | -606K | 3.24M | -4.59M | 2.22M | 1.71M | -842.84K | 1.28M |
Accounts payable | 396K | -801K | -1.91M | -1.13M | 460K | -512K | 931K | 897K | 659.41K | -1.25K |
Cash generated by operating activities | -25.78M | -23.10M | -56.65M | -77.56M | -74.78M | -72.98M | -50.44M | -35.72M | -57.30M | -7.61M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -59.33M | -54.89M | -33.27M | -101.64M | 0 | 0 |
Investments In Property Plant And Equipment | -21K | -7K | -625K | -522K | -1.61M | -12.13M | -7.22M | -5.42M | -804.12K | -366.33K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -21K | 893K | 14.08M | 48.85M | 10.41M | -3.25M | 2.05M | -86.45M | -804.12K | -366.33K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 22.90M | 8.97M | 64.86M | 64.86M | 369K | 347K | 160.60M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -155.39K | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.05M | -6.65K |
Repayments of term debt | 0 | -35K | -37.22M | 0 | -31K | 0 | -15K | 0 | -1.18M | -200K |
Cash used in financing activities | 0 | 32.87M | -14.23M | 74.08M | 68.10M | 78.48M | 20.92M | 818K | 238.54M | 17.51M |
Net Change In Cash | -25.82M | 10.66M | -56.82M | 45.14M | 3.63M | 2.24M | -27.46M | -121.36M | 180.43M | 9.53M |
Cash at end of period | 21.83M | 47.65M | 36.99M | 93.81M | 48.66M | 45.02M | 42.78M | 70.24M | 191.60M | 11.16M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |